Sorry, this entry is only available in German!
MSD erhält EU-Zulassung für ISENTRESS(R) (Raltegravir) zur Kombinationstherapie bei HIV-1-infizierten Kindern
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.